Financial Guidance
Preliminary unaudited financial guidance for the third quarter of 2022:
Revenue: The Company anticipates reporting third quarter 2022 revenue of
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued four patents related to its non-invasive
According to data from Benzinga Pro, during Q2, electroCore's (NASDAQ:ECOR) reported sales totaled $2.16 million. Despite a 4.39% increase in earnings, the company posted a loss of $5.34 million.
electroCore (NASDAQ:ECOR) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
electroCore missed estimated earnings by 14.29%, reporting an EPS of $-0.08 versus an estimate of $-0.07.
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 33.33 percent decrease over losses of $(0.06) per share from the